Market Access For life sciences, it’s not only about when to bring on a GC... For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next.
Market Access A step forward, but not the finish line: What NICE’s QALY up... Healthcare in the UK is at an inflection point.
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Market Access BIO-Europe Spring 2026: In conversation with Marjorie Sidhou... Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.
Market Access In DTC's watershed moment, trust and partnership are key More and more pharma companies are turning to direct-to-patient access models. But the consensus at Reuters Pharma USA is that they can't do it alone.
Market Access BIO-Europe Spring, Portugal: Propelling new wave innovation BIO-Europe Spring arrived in Lisbon, Portugal yesterday, running from 23rd to 25th March.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
